Helixgate https://validator.w3.org/feed/docs/rss2.html Home Biopharma M&A maintains strength even as large deals wane STAT+: Takeda will pay $13.6 million to settle allegations it paid kickbacks to doctors ASGCT Q1 Landscape Report Paints Positive Picture for Gene and RNA Therapy FDA hold puts Aardvark Prader-Willi drug in limbo Candel reports prostate cancer drug’s long-term data ahead of FDA filing Opinion: First hantavirus, now Ebola: What two outbreaks reveal about global preparedness Employment and funding growth fell in 2025: California Life Sciences report Sun Pharma recalls cancer drug after finding glass particles in some vials STAT+: A political contest in the U.K. could shake up drug pricing Biogen’s Alzheimer’s results bolster tau theory—and Denali’s next gen candidate ASGCT 2026: Beverly Davidson Offers Vehicle and Route for Huntington’s Disease Gene Therapy ASGCT 2026: Rare Instance of AAV Integration into Human Genome Linked to Brain Tumor #ASGCT26: A Zillow-like marketplace for abandoned gene therapies goes live Supreme Court preserves access to widely used abortion pill, while lawsuit plays out Aardvark’s next move after clinical hold; Alumis’ verdict on Acelyrin asset Future of Aardvark’s Prader-Willi drug in doubt as FDA slaps full hold on program CREATE jumps into CAR T competition with $122M series B Implantable Living Materials Contain Infection-Sensing Bacteria That Release Therapeutics Makary’s departure and Cassidy’s tenuous Senate seat Interim CDER head Høeg is out days after Makary: report M&A isn’t just for big pharma. Mid-size companies are stepping up deal hunts Encoded’s gene therapy reduced seizures in Dravet syndrome Encoded’s gene therapy reduced seizures in Dravet syndrome Molecular Anchors Help Tumor Therapies Stay Longer on Cancer Cells Why isn’t alcohol seen as a public health emergency? Supreme Court preserves mail access for abortion pill PSA screening for prostate cancer reduces disease-specific deaths, new review shows STAT investigates the epidemic killing 178,000 Americans a year ASGCT dispatch: In vivo CAR-T is everywhere, but still preclinical STAT+: CDC plans to transfer monkeys to nonprofit’s sanctuary as it seeks to reduce animal testing Andrea Pfeifer ends 23-year reign at AC Immune; Acadia’s top R&D exec announces retirement GPCRs, radiopharma and the rise of functional peptide screening Chutes & Ladders—AC Immune CEO bids adieu Infinitopes appoints CSO to advance immuno-oncology pipeline  Create Medicines raises $122M to bolster in vivo CAR-T therapies Drugmakers have to go through rigorous tests to get a lower tariff rate DNA‑Guided CRISPR Suggests a New Direction for RNA Editing Degron, CREATE, TenNor raise capital; Cabaletta posts CAR-T data REGENXBIO slumps after serious side effects mar Duchenne gene therapy results STAT+: BeOne wins FDA approval in lymphoma race Biogen takes tau Alzheimer’s therapy to Phase 3 despite mid-stage fail, prompting cautious optimism How Penn Medicine plans to use AI to train their doctors Opinion: Tributes to Craig Venter and the genomics race are missing something important Biotech leaders pitch Pazdur as next FDA chief Degron adds $40M to series A, supporting immunology plans for molecular glue platform Alumis pulls back from would-be rival to Amgen’s Tepezza after assessing prospects STAT+: Three years of declining overdose deaths begets cautious optimism and some concerns Biogen’s anti-tau Alzheimer’s drug misses Phase 2 goal, but claims signs of efficacy Aardvark to dig into phase 3 data early after FDA imposes hold